| 达比加群酯用于心房颤动射频消融围手术期的有效性和安全性 |
| |
| 引用本文： | 龙毅,刘凡. 达比加群酯用于心房颤动射频消融围手术期的有效性和安全性[J]. 心脏杂志, 2015, 27(1): 110-114 |
| |
| 作者姓名： | 龙毅 刘凡 |
| |
| 作者单位： | (重庆市中医院心血管内科,重庆 400011) |
| |
| 摘 要： | 达比加群酯已被批准用于预防非瓣膜性房颤(atrial fibrillation,AF)的卒中及体循环栓塞。然而在AF导管消融围手术期使用达比加群酯的有效性和安全性并未得到充分的研究,本文旨在评估达比加群酯用于AF射频消融围手术期的有效性和安全性。
|
| 关 键 词： | 达比加群酯 心房颤动 射频消融 围手术期 抗凝 |
| 收稿时间： | 2014-01-13 |
Efficacy and safety of periprocedural dabigatran in patients undergoing catheter ablation of atrial fibrillation |
| |
| LONG Yi;LIU Fan. Efficacy and safety of periprocedural dabigatran in patients undergoing catheter ablation of atrial fibrillation[J]. Chinese Heart Journal, 2015, 27(1): 110-114 |
| |
| Authors: | LONG Yi LIU Fan |
| |
| Affiliation: | LONG Yi;LIU Fan;Department of Cardiology,Hospital of Traditional Chinese Medicine; |
| |
| Abstract: | Dabigatran was approved for the prevention of stroke or systemic embolism in patients with nonvalvular atrial fibrillation (AF). However, the safety and efficacy of dabigatran for periprocedural anticoagulation in the setting of AF ablation are not well studied. This article reviews the safety and effectiveness of periprocedural dabigatran for anticoagulation in patients undergoing AF ablation. |
| |
| Keywords: | |
| 本文献已被 CNKI 等数据库收录！ |
| 点击此处可从《心脏杂志》浏览原始摘要信息 |
|
点击此处可从《心脏杂志》下载免费的PDF全文 |
